Home >> News >> Pharmaceutical CDMO Services Market Is Expected To Reach US$ 116.2 Bn By 2026

Pharmaceutical CDMO Services Market Is Expected To Reach US$ 116.2 Bn By 2026

The latest market report published by Acute Market Reports, Inc. “Pharmaceutical CDMO Services Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global Pharmaceutical CDMO Services Market was estimated at US$ 65.6 Bn in 2017 expanding at a CAGR of 6.5% from 2018 to 2026, to reach US$ 116.2 Bn by 2026.

Market Insights

Over recent years, pharmaceutical companies are facing a pressing need for consolidating their supplier base while containing development and manufacturing costs. The global pharmaceutical market is rapidly changing while posing new challenges for pharmaceutical companies, where growing pricing pressure being the most prominent issue. However, changing macro-environment due to the aging population, emerging middle-income population groups and fast progressing R&D innovation have driven pharmaceutical companies to rework on their supply chains. Pharmaceutical companies are rethinking whether to invest in infrastructure expansion or explore core competencies. This has led to the evolution of contract development and manufacturing organization partners.

Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/pharmaceutical-cdmo-services-market

The global pharmaceutical CDMO services market is experiencing greater growth than the overall pharmaceuticals market. The market growth is driven by prime factors such as improved resource quality, increasing trend of outsourcing by pharma companies for cost optimization and increase in the use of pharmaceuticals, and global growth of generic pharmaceutical companies. Additional drivers of this market include the need of large pharmaceutical companies to counterbalance their manufacturing capacity constraints and procure access to technologies that are not available with them. Increasing integration of pharmaceutical companies and CDMOs is also witnessed in the market with respect to collaborative and strategic partnerships to offset supply chain issues.

For building optimum strategic partnerships between pharma companies and CDMOs a prime factor considered by manufacturers is the precise forecasting of future manufacturing volume. At present this poses a major challenge due to volatile competition and reimbursement scenario. Therefore, pharma companies are increasingly seeking a flexible business model that will efficiently adjust to the changes in real-time demand. This has resulted in CDMOs adopting the condominium business approach. CDMOs are offering specialized platforms to pharmaceutical companies by providing custom facilities within the CDMO infrastructure for new products with unique characteristics.  Engaging with CDMOs provides design services to the pharma companies while entering into synergy with equipment suppliers, ensuring valid manufacturing processes and efficient operation management. Adoption of such business models ensures success in the forms such as efficient management of scalability, speed to market, better product quality, reduced operating cost, and smaller operational footprint.

Fort the purpose of this study, the global CDMO services market is segmented in terms of service and product types. Among the service types, drug substance development and manufacturing leads the global market in terms of revenue. Whereas the innovator drugs segment is the most sought after area where CDMO services are demanded. Additionally, North America is the largest regional market for CDMO services and is primarily characterized by increasing pricing pressure from payers and governments, and widespread domicile of CDMO companies in the region. Increasing outsourcing to the Asia Pacific for efficient management of supply chain and cost reduction is a key factor rendering the fastest market growth of this region.

Key Market Movements:

  • Significant growth in demand for generic drugs
  • Increasing middle-income population groups with the growing demand for super generic drugs
  • Large preference for outsourcing development and manufacturing of innovator drugs for cost mitigation
  • Spreading market consolidation strategies undertaken by large CDMOs to increase their specialization while offering one-stop-shop services to customers

Access Free Sample Copy of Research Report: https://www.acutemarketreports.com/request-free-sample/138409

List of Companies Covered:

  • Recipharm AB
  • AMRI Global
  • Patheon N.V.
  • Aenova Group
  • Catalent, Inc.
  • Amatsigroup
  • WuXi AppTec Group
  • Strides Pharma Science Limited(Strides)
  • Piramal Pharma Solutions
  • Siegfried Ltd
  • Fareva Group
  • FAMAR Health Care Services

Market Segmentation:

By Service Type

 • Drug Substance Development and Manufacturing

 • Specialized Services

 • Lab-based Services

 By Product Type

 • Innovator Drugs

 • Generic Drugs

 • Label Change

 • Others

By Geography Segment Type

  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of the World (the Middle East & Africa, Latin America)

Access Free Sample Copy of Research Report: https://www.acutemarketreports.com/request-free-sample/138409

Leave a Reply

Your email address will not be published. Required fields are marked *